Review



cryovial bead preservation system  (Pro-Lab Diagnostics)


Bioz Verified Symbol Pro-Lab Diagnostics is a verified supplier
Bioz Manufacturer Symbol Pro-Lab Diagnostics manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97

    Structured Review

    Pro-Lab Diagnostics cryovial bead preservation system
    Cryovial Bead Preservation System, supplied by Pro-Lab Diagnostics, used in various techniques. Bioz Stars score: 97/100, based on 1786 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cryovial bead preservation system/product/Pro-Lab Diagnostics
    Average 97 stars, based on 1786 article reviews
    cryovial bead preservation system - by Bioz Stars, 2026-03
    97/100 stars

    Images



    Similar Products

    96
    Thermo Fisher cryogenic tubes cryovials
    Cryogenic Tubes Cryovials, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cryogenic tubes cryovials/product/Thermo Fisher
    Average 96 stars, based on 1 article reviews
    cryogenic tubes cryovials - by Bioz Stars, 2026-03
    96/100 stars
      Buy from Supplier

    97
    Pro-Lab Diagnostics cryovial bead preservation system
    Cryovial Bead Preservation System, supplied by Pro-Lab Diagnostics, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cryovial bead preservation system/product/Pro-Lab Diagnostics
    Average 97 stars, based on 1 article reviews
    cryovial bead preservation system - by Bioz Stars, 2026-03
    97/100 stars
      Buy from Supplier

    94
    Cell Applications Inc control rat pulmonary artery smooth muscle cells rpasmcs
    A , Proliferative capacity of <t>rPASMCs</t> in the hnRNPA1 siRNA-treated group compared with that in the negative control siRNA-treated group, as measured using the CCK-8 assay. B , rPSAMCs stained with Hoechst dye 72 h after siRNA transfection. C , Number of rPASMCs adhering to the bottom of 96-well plates 72 h after siRNA transfection. D , Proliferative capacity of rPASMCs in the hnRNPA1 siRNA-treated group compared with the negative control siRNA-treated group via Ki-67 staining. E , Apoptosis of rPASMCs evaluated by cleaved caspase 3 expression in the hnRNPA1 siRNA-treated group compared with that in the negative control siRNA-treated group by staining for cleaved caspase 3. Orange, yellow, blue, and green colors show normoxia + control siRNA, normoxia + hnRNPA1 siRNA, hypoxia + control siRNA, and hypoxia + hnRNPA1 siRNA, respectively. * P < 0.05; ** P < 0.01. Statistical analysis was performed using the Wilcoxon signed-rank test. Values are the mean ± SE, n = 6 per group. CCK, cell counting kit; hnRNPA1, heterogeneous nuclear ribonucleoprotein A1; rPASMC, rat pulmonary artery smooth muscle cell; siRNA, small interfering RNA.
    Control Rat Pulmonary Artery Smooth Muscle Cells Rpasmcs, supplied by Cell Applications Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/control rat pulmonary artery smooth muscle cells rpasmcs/product/Cell Applications Inc
    Average 94 stars, based on 1 article reviews
    control rat pulmonary artery smooth muscle cells rpasmcs - by Bioz Stars, 2026-03
    94/100 stars
      Buy from Supplier

    97
    Pro-Lab Diagnostics cryovials
    A , Proliferative capacity of <t>rPASMCs</t> in the hnRNPA1 siRNA-treated group compared with that in the negative control siRNA-treated group, as measured using the CCK-8 assay. B , rPSAMCs stained with Hoechst dye 72 h after siRNA transfection. C , Number of rPASMCs adhering to the bottom of 96-well plates 72 h after siRNA transfection. D , Proliferative capacity of rPASMCs in the hnRNPA1 siRNA-treated group compared with the negative control siRNA-treated group via Ki-67 staining. E , Apoptosis of rPASMCs evaluated by cleaved caspase 3 expression in the hnRNPA1 siRNA-treated group compared with that in the negative control siRNA-treated group by staining for cleaved caspase 3. Orange, yellow, blue, and green colors show normoxia + control siRNA, normoxia + hnRNPA1 siRNA, hypoxia + control siRNA, and hypoxia + hnRNPA1 siRNA, respectively. * P < 0.05; ** P < 0.01. Statistical analysis was performed using the Wilcoxon signed-rank test. Values are the mean ± SE, n = 6 per group. CCK, cell counting kit; hnRNPA1, heterogeneous nuclear ribonucleoprotein A1; rPASMC, rat pulmonary artery smooth muscle cell; siRNA, small interfering RNA.
    Cryovials, supplied by Pro-Lab Diagnostics, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cryovials/product/Pro-Lab Diagnostics
    Average 97 stars, based on 1 article reviews
    cryovials - by Bioz Stars, 2026-03
    97/100 stars
      Buy from Supplier

    97
    Pro-Lab Diagnostics microbank cryovials
    A , Proliferative capacity of <t>rPASMCs</t> in the hnRNPA1 siRNA-treated group compared with that in the negative control siRNA-treated group, as measured using the CCK-8 assay. B , rPSAMCs stained with Hoechst dye 72 h after siRNA transfection. C , Number of rPASMCs adhering to the bottom of 96-well plates 72 h after siRNA transfection. D , Proliferative capacity of rPASMCs in the hnRNPA1 siRNA-treated group compared with the negative control siRNA-treated group via Ki-67 staining. E , Apoptosis of rPASMCs evaluated by cleaved caspase 3 expression in the hnRNPA1 siRNA-treated group compared with that in the negative control siRNA-treated group by staining for cleaved caspase 3. Orange, yellow, blue, and green colors show normoxia + control siRNA, normoxia + hnRNPA1 siRNA, hypoxia + control siRNA, and hypoxia + hnRNPA1 siRNA, respectively. * P < 0.05; ** P < 0.01. Statistical analysis was performed using the Wilcoxon signed-rank test. Values are the mean ± SE, n = 6 per group. CCK, cell counting kit; hnRNPA1, heterogeneous nuclear ribonucleoprotein A1; rPASMC, rat pulmonary artery smooth muscle cell; siRNA, small interfering RNA.
    Microbank Cryovials, supplied by Pro-Lab Diagnostics, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/microbank cryovials/product/Pro-Lab Diagnostics
    Average 97 stars, based on 1 article reviews
    microbank cryovials - by Bioz Stars, 2026-03
    97/100 stars
      Buy from Supplier

    94
    Miltenyi Biotec cryovial
    A , Proliferative capacity of <t>rPASMCs</t> in the hnRNPA1 siRNA-treated group compared with that in the negative control siRNA-treated group, as measured using the CCK-8 assay. B , rPSAMCs stained with Hoechst dye 72 h after siRNA transfection. C , Number of rPASMCs adhering to the bottom of 96-well plates 72 h after siRNA transfection. D , Proliferative capacity of rPASMCs in the hnRNPA1 siRNA-treated group compared with the negative control siRNA-treated group via Ki-67 staining. E , Apoptosis of rPASMCs evaluated by cleaved caspase 3 expression in the hnRNPA1 siRNA-treated group compared with that in the negative control siRNA-treated group by staining for cleaved caspase 3. Orange, yellow, blue, and green colors show normoxia + control siRNA, normoxia + hnRNPA1 siRNA, hypoxia + control siRNA, and hypoxia + hnRNPA1 siRNA, respectively. * P < 0.05; ** P < 0.01. Statistical analysis was performed using the Wilcoxon signed-rank test. Values are the mean ± SE, n = 6 per group. CCK, cell counting kit; hnRNPA1, heterogeneous nuclear ribonucleoprotein A1; rPASMC, rat pulmonary artery smooth muscle cell; siRNA, small interfering RNA.
    Cryovial, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cryovial/product/Miltenyi Biotec
    Average 94 stars, based on 1 article reviews
    cryovial - by Bioz Stars, 2026-03
    94/100 stars
      Buy from Supplier

    Image Search Results


    A , Proliferative capacity of rPASMCs in the hnRNPA1 siRNA-treated group compared with that in the negative control siRNA-treated group, as measured using the CCK-8 assay. B , rPSAMCs stained with Hoechst dye 72 h after siRNA transfection. C , Number of rPASMCs adhering to the bottom of 96-well plates 72 h after siRNA transfection. D , Proliferative capacity of rPASMCs in the hnRNPA1 siRNA-treated group compared with the negative control siRNA-treated group via Ki-67 staining. E , Apoptosis of rPASMCs evaluated by cleaved caspase 3 expression in the hnRNPA1 siRNA-treated group compared with that in the negative control siRNA-treated group by staining for cleaved caspase 3. Orange, yellow, blue, and green colors show normoxia + control siRNA, normoxia + hnRNPA1 siRNA, hypoxia + control siRNA, and hypoxia + hnRNPA1 siRNA, respectively. * P < 0.05; ** P < 0.01. Statistical analysis was performed using the Wilcoxon signed-rank test. Values are the mean ± SE, n = 6 per group. CCK, cell counting kit; hnRNPA1, heterogeneous nuclear ribonucleoprotein A1; rPASMC, rat pulmonary artery smooth muscle cell; siRNA, small interfering RNA.

    Journal: bioRxiv

    Article Title: Heterogeneous Nuclear Ribonucleoprotein A1 as a Key Regulator in Pulmonary Arterial Hypertension Development

    doi: 10.64898/2026.01.05.697826

    Figure Lengend Snippet: A , Proliferative capacity of rPASMCs in the hnRNPA1 siRNA-treated group compared with that in the negative control siRNA-treated group, as measured using the CCK-8 assay. B , rPSAMCs stained with Hoechst dye 72 h after siRNA transfection. C , Number of rPASMCs adhering to the bottom of 96-well plates 72 h after siRNA transfection. D , Proliferative capacity of rPASMCs in the hnRNPA1 siRNA-treated group compared with the negative control siRNA-treated group via Ki-67 staining. E , Apoptosis of rPASMCs evaluated by cleaved caspase 3 expression in the hnRNPA1 siRNA-treated group compared with that in the negative control siRNA-treated group by staining for cleaved caspase 3. Orange, yellow, blue, and green colors show normoxia + control siRNA, normoxia + hnRNPA1 siRNA, hypoxia + control siRNA, and hypoxia + hnRNPA1 siRNA, respectively. * P < 0.05; ** P < 0.01. Statistical analysis was performed using the Wilcoxon signed-rank test. Values are the mean ± SE, n = 6 per group. CCK, cell counting kit; hnRNPA1, heterogeneous nuclear ribonucleoprotein A1; rPASMC, rat pulmonary artery smooth muscle cell; siRNA, small interfering RNA.

    Article Snippet: Control rat pulmonary artery smooth muscle cells (rPASMCs) were purchased from Cell Applications, USA (Cat# CAR35205a) and cultured in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum and 1% penicillin–streptomycin in a humidified incubator at 37 °C with 5% CO 2 .

    Techniques: Negative Control, CCK-8 Assay, Staining, Transfection, Expressing, Control, Cell Counting, Small Interfering RNA

    A , hnRNPA1, IQGAP1, PKM2 and β-actin protein expression in normal rPASMCs and hypoxia-treated rPASMCs treated with negative control siRNA or hnRNPA1 siRNA. B–D , Ratio of hnRNPA1/β-actin (B) PKM2/β-actin (C) and IQGAP1/β-actin (D) in normal rPASMCs and hypoxia-treated rPASMCs treated with negative control or hnRNPA1 siRNAs. Orange, yellow, blue, and green colors show normoxia + control siRNA, normoxia + hnRNPA1 siRNA, hypoxia + control siRNA, and hypoxia + hnRNPA1 siRNA, respectively. * P < 0.05; ** P < 0.01. Statistical analysis was performed using the Wilcoxon signed-rank test. Values are the mean ± SE, n = 6 per group. hnRNPA1, heterogeneous nuclear ribonucleoprotein A1; IQGAP1, IQ motif containing GTPase activating protein 1; PKM2, pyruvate kinase M 2; rPASMC, rat pulmonary artery smooth muscle cell; siRNA, small interfering RNA.

    Journal: bioRxiv

    Article Title: Heterogeneous Nuclear Ribonucleoprotein A1 as a Key Regulator in Pulmonary Arterial Hypertension Development

    doi: 10.64898/2026.01.05.697826

    Figure Lengend Snippet: A , hnRNPA1, IQGAP1, PKM2 and β-actin protein expression in normal rPASMCs and hypoxia-treated rPASMCs treated with negative control siRNA or hnRNPA1 siRNA. B–D , Ratio of hnRNPA1/β-actin (B) PKM2/β-actin (C) and IQGAP1/β-actin (D) in normal rPASMCs and hypoxia-treated rPASMCs treated with negative control or hnRNPA1 siRNAs. Orange, yellow, blue, and green colors show normoxia + control siRNA, normoxia + hnRNPA1 siRNA, hypoxia + control siRNA, and hypoxia + hnRNPA1 siRNA, respectively. * P < 0.05; ** P < 0.01. Statistical analysis was performed using the Wilcoxon signed-rank test. Values are the mean ± SE, n = 6 per group. hnRNPA1, heterogeneous nuclear ribonucleoprotein A1; IQGAP1, IQ motif containing GTPase activating protein 1; PKM2, pyruvate kinase M 2; rPASMC, rat pulmonary artery smooth muscle cell; siRNA, small interfering RNA.

    Article Snippet: Control rat pulmonary artery smooth muscle cells (rPASMCs) were purchased from Cell Applications, USA (Cat# CAR35205a) and cultured in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum and 1% penicillin–streptomycin in a humidified incubator at 37 °C with 5% CO 2 .

    Techniques: Expressing, Negative Control, Control, Small Interfering RNA

    A , hnRNPA1 and β-actin protein expression in hypoxia-treated rPASMCs treated with tetracaine. B , Ratio of hnRNPA1/β-actin in hypoxia-treated rPASMCs treated with tetracaine. C , Proliferative capacity of hypoxia-treated rPASMCs treated with tetracaine, measured via the CCK-8 assay. D , rPSAMCs stained with Hoechst dye 72 h after tetracaine treatment. E , Number of rPASMCs adhering to the bottom of 96-well plates 72 h after tetracaine treatment. * P < 0.05; ** P < 0.01. Statistical analysis was performed using the Wilcoxon signed-rank test. Values are the mean ± SE, n = 3 per group. CCK, cell counting kit; hnRNPA1, heterogeneous nuclear ribonucleoprotein A1; rPASMC, rat pulmonary artery smooth muscle cell.

    Journal: bioRxiv

    Article Title: Heterogeneous Nuclear Ribonucleoprotein A1 as a Key Regulator in Pulmonary Arterial Hypertension Development

    doi: 10.64898/2026.01.05.697826

    Figure Lengend Snippet: A , hnRNPA1 and β-actin protein expression in hypoxia-treated rPASMCs treated with tetracaine. B , Ratio of hnRNPA1/β-actin in hypoxia-treated rPASMCs treated with tetracaine. C , Proliferative capacity of hypoxia-treated rPASMCs treated with tetracaine, measured via the CCK-8 assay. D , rPSAMCs stained with Hoechst dye 72 h after tetracaine treatment. E , Number of rPASMCs adhering to the bottom of 96-well plates 72 h after tetracaine treatment. * P < 0.05; ** P < 0.01. Statistical analysis was performed using the Wilcoxon signed-rank test. Values are the mean ± SE, n = 3 per group. CCK, cell counting kit; hnRNPA1, heterogeneous nuclear ribonucleoprotein A1; rPASMC, rat pulmonary artery smooth muscle cell.

    Article Snippet: Control rat pulmonary artery smooth muscle cells (rPASMCs) were purchased from Cell Applications, USA (Cat# CAR35205a) and cultured in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum and 1% penicillin–streptomycin in a humidified incubator at 37 °C with 5% CO 2 .

    Techniques: Expressing, CCK-8 Assay, Staining, Cell Counting